DE59206403D1 - Verwendung von Xanthinderivaten zur Herstellung eines Arzneimittels zur Behandlung von sekundären Nervenzellschäden und Funktionsstörungen nach Schädel-Hirn-Traumen - Google Patents
Verwendung von Xanthinderivaten zur Herstellung eines Arzneimittels zur Behandlung von sekundären Nervenzellschäden und Funktionsstörungen nach Schädel-Hirn-TraumenInfo
- Publication number
- DE59206403D1 DE59206403D1 DE59206403T DE59206403T DE59206403D1 DE 59206403 D1 DE59206403 D1 DE 59206403D1 DE 59206403 T DE59206403 T DE 59206403T DE 59206403 T DE59206403 T DE 59206403T DE 59206403 D1 DE59206403 D1 DE 59206403D1
- Authority
- DE
- Germany
- Prior art keywords
- manufacture
- treatment
- medicament
- xanthine derivatives
- brain injury
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical class O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- 239000003814 drug Substances 0.000 title abstract 2
- 229940083747 low-ceiling diuretics xanthine derivative Drugs 0.000 title abstract 2
- 238000004519 manufacturing process Methods 0.000 title abstract 2
- 208000030886 Traumatic Brain injury Diseases 0.000 title 1
- 230000005779 cell damage Effects 0.000 title 1
- 208000037887 cell injury Diseases 0.000 title 1
- 210000002569 neuron Anatomy 0.000 title 1
- 230000009529 traumatic brain injury Effects 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 4
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- 125000005188 oxoalkyl group Chemical group 0.000 abstract 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 1
- 206010019196 Head injury Diseases 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 150000002431 hydrogen Chemical class 0.000 abstract 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 abstract 1
- 125000004430 oxygen atom Chemical group O* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE59206403T DE59206403D1 (de) | 1991-07-11 | 1992-07-10 | Verwendung von Xanthinderivaten zur Herstellung eines Arzneimittels zur Behandlung von sekundären Nervenzellschäden und Funktionsstörungen nach Schädel-Hirn-Traumen |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE4122884 | 1991-07-11 | ||
| DE4217639 | 1992-05-28 | ||
| DE59206403T DE59206403D1 (de) | 1991-07-11 | 1992-07-10 | Verwendung von Xanthinderivaten zur Herstellung eines Arzneimittels zur Behandlung von sekundären Nervenzellschäden und Funktionsstörungen nach Schädel-Hirn-Traumen |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE59206403D1 true DE59206403D1 (de) | 1996-07-04 |
Family
ID=25905369
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE59206403T Expired - Lifetime DE59206403D1 (de) | 1991-07-11 | 1992-07-10 | Verwendung von Xanthinderivaten zur Herstellung eines Arzneimittels zur Behandlung von sekundären Nervenzellschäden und Funktionsstörungen nach Schädel-Hirn-Traumen |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US5409935A (enExample) |
| EP (1) | EP0528164B1 (enExample) |
| JP (1) | JP3436547B2 (enExample) |
| KR (1) | KR100237945B1 (enExample) |
| AT (1) | ATE138573T1 (enExample) |
| AU (1) | AU649851B2 (enExample) |
| CA (1) | CA2073633C (enExample) |
| CZ (2) | CZ281480B6 (enExample) |
| DE (1) | DE59206403D1 (enExample) |
| DK (1) | DK0528164T3 (enExample) |
| ES (1) | ES2088519T3 (enExample) |
| GR (1) | GR3020233T3 (enExample) |
| HU (1) | HU217983B (enExample) |
| IE (1) | IE74888B1 (enExample) |
| IL (1) | IL102456A (enExample) |
| MX (1) | MX9203323A (enExample) |
| PH (1) | PH30341A (enExample) |
| RU (1) | RU2126407C1 (enExample) |
| SK (1) | SK280537B6 (enExample) |
| TW (1) | TW210285B (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5648357A (en) * | 1992-03-04 | 1997-07-15 | Cell Therapeutics, Inc. | Enatiomerically pure hydroxylated xanthine compounds |
| US5567704A (en) * | 1992-03-04 | 1996-10-22 | Cell Therapeutics, Inc. | R-enatiomerically pure hydroxylated xanthine compounds to treat baldness |
| CA2112239C (en) * | 1992-03-04 | 2000-05-09 | James A. Bianco | Enantiomeric hydroxylated xanthine compounds |
| EP0570831A2 (de) * | 1992-05-20 | 1993-11-24 | Hoechst Aktiengesellschaft | Verwendung von Xanthinderivaten zur Behandlung von Nervenschädigungen nach Unterbrechung der Blutzirkulation |
| WO1995013075A1 (en) * | 1993-11-12 | 1995-05-18 | Cell Therapeutics, Inc. | Method for preventing tissue injury from hypoxia |
| US5856330A (en) * | 1996-07-31 | 1999-01-05 | Hoechst Aktiengesellschaft | Use of xanthine derivatives for the inhibition of dephosphorylation of cofilin |
| US5981536A (en) * | 1996-07-31 | 1999-11-09 | Hoechst Aktiengesellschaft | Use of xanthine derivatives for the modulation of apoptosis |
| IL150150A0 (en) * | 2000-01-14 | 2002-12-01 | Schering Ag | 1,2-diaryl benzimidazoles for treating illnesses associated with a microglia activation |
| US7115645B2 (en) | 2000-01-14 | 2006-10-03 | Schering Aktiengesellschaft | 1,2 diarylbenzimidazoles and their pharmaceutical use |
| US7329679B2 (en) | 2000-01-27 | 2008-02-12 | Schering Aktiengesellschaft | 1,2 Diarylbenzimidazoles and their pharmaceutical use |
| US20040110776A1 (en) * | 2002-02-22 | 2004-06-10 | Iok-Hou Pang | Use of propentofylline to control intraocular pressure |
| EP1515972B1 (en) * | 2002-06-12 | 2009-05-13 | F. Hoffmann-La Roche Ag | Amide substituted xanthine derivatives with gluconeogenesis modulating activity |
| WO2005037286A1 (en) * | 2003-03-25 | 2005-04-28 | Vasopharm Biotech Gmbh | Use of pteridine derivatives for the treatment of increased intracranial pressure and secondary ischemia |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2330742C2 (de) * | 1973-06-16 | 1982-07-29 | Hoechst Ag, 6000 Frankfurt | 1-(Oxoalkyl)-3-methyl-7-alkylxanthine, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel |
| CH608236A5 (enExample) * | 1974-01-22 | 1978-12-29 | Wuelfing J A Fa | |
| US4275064A (en) * | 1976-02-06 | 1981-06-23 | Interx Research Corporation | Transient pro-drug forms of xanthine derivatives and their use as topical anti-inflammatory agents |
| FR2531085A1 (fr) * | 1982-07-28 | 1984-02-03 | Adir | Nouveaux derives de la xanthine, leur procede de preparation et les compositions pharmaceutiques les renfermant |
| IT1200944B (it) * | 1982-08-10 | 1989-01-27 | Malesci Sas | Derivati xantinici,procedimento per la loro preparazione,composizione farmaceutiche che il contengono e loro impiego terapeutico |
| US4567183A (en) * | 1983-03-11 | 1986-01-28 | Analgesic Associates | Analgesic and anti-inflammatory compositions comprising xanthines and methods of using same |
| JPS6110715A (ja) * | 1984-06-26 | 1986-01-18 | Fanuc Ltd | 絶対位置検出方式 |
| JPH062675B2 (ja) * | 1985-04-05 | 1994-01-12 | ヘキストジヤパン株式会社 | 記憶障害治療剤 |
| DE3525801A1 (de) * | 1985-07-19 | 1987-01-22 | Hoechst Ag | Tertiaere hydroxyalkylxanthine, verfahren zu ihrer herstellung, die sie enthaltenden arzneimittel und ihre verwendung |
| IT1197516B (it) * | 1986-12-24 | 1988-11-30 | Abc Ist Biolog Chem Spa | Derivati teofillinmetilanici e teofillinmetilditianici procedimento per la loro preparazione e composizioni farmaceutiche che li comprendono |
| IT1229195B (it) * | 1989-03-10 | 1991-07-25 | Poli Ind Chimica Spa | Derivati xantinici ad attivita' broncodilatatrice e loro applicazioni terapeutiche. |
| GB8929208D0 (en) * | 1989-12-27 | 1990-02-28 | Almirall Lab | New xanthine derivatives |
-
1992
- 1992-06-25 MX MX9203323A patent/MX9203323A/es unknown
- 1992-07-09 US US07/909,389 patent/US5409935A/en not_active Expired - Lifetime
- 1992-07-09 IL IL10245692A patent/IL102456A/en not_active IP Right Cessation
- 1992-07-09 PH PH44627A patent/PH30341A/en unknown
- 1992-07-09 HU HU9202273A patent/HU217983B/hu unknown
- 1992-07-10 CZ CS922160A patent/CZ281480B6/cs not_active IP Right Cessation
- 1992-07-10 AT AT92111761T patent/ATE138573T1/de active
- 1992-07-10 IE IE922259A patent/IE74888B1/en not_active IP Right Cessation
- 1992-07-10 CZ CZ96816A patent/CZ81696A3/cs not_active IP Right Cessation
- 1992-07-10 SK SK2160-92A patent/SK280537B6/sk not_active IP Right Cessation
- 1992-07-10 JP JP18328592A patent/JP3436547B2/ja not_active Expired - Lifetime
- 1992-07-10 ES ES92111761T patent/ES2088519T3/es not_active Expired - Lifetime
- 1992-07-10 EP EP92111761A patent/EP0528164B1/de not_active Expired - Lifetime
- 1992-07-10 DE DE59206403T patent/DE59206403D1/de not_active Expired - Lifetime
- 1992-07-10 KR KR1019920012268A patent/KR100237945B1/ko not_active Expired - Lifetime
- 1992-07-10 CA CA002073633A patent/CA2073633C/en not_active Expired - Lifetime
- 1992-07-10 RU RU94027686/04A patent/RU2126407C1/ru active
- 1992-07-10 AU AU19591/92A patent/AU649851B2/en not_active Expired
- 1992-07-10 DK DK92111761.0T patent/DK0528164T3/da active
- 1992-07-25 TW TW081105886A patent/TW210285B/zh not_active IP Right Cessation
-
1996
- 1996-06-13 GR GR960401607T patent/GR3020233T3/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HUT61763A (en) | 1993-03-01 |
| KR100237945B1 (ko) | 2000-02-01 |
| TW210285B (enExample) | 1993-08-01 |
| CZ281480B6 (cs) | 1996-10-16 |
| SK216092A3 (en) | 1995-09-13 |
| PH30341A (en) | 1997-04-02 |
| IL102456A (en) | 1996-10-16 |
| IE922259A1 (en) | 1993-01-13 |
| HU217983B (hu) | 2000-05-28 |
| MX9203323A (es) | 1994-07-29 |
| ES2088519T3 (es) | 1996-08-16 |
| EP0528164A3 (enExample) | 1994-03-02 |
| IL102456A0 (en) | 1993-01-14 |
| RU94027686A (ru) | 1996-05-27 |
| EP0528164A2 (de) | 1993-02-24 |
| AU649851B2 (en) | 1994-06-02 |
| KR930001911A (ko) | 1993-02-22 |
| HU9202273D0 (en) | 1992-10-28 |
| ATE138573T1 (de) | 1996-06-15 |
| IE74888B1 (en) | 1997-08-13 |
| CZ282140B6 (cs) | 1997-05-14 |
| EP0528164B1 (de) | 1996-05-29 |
| JP3436547B2 (ja) | 2003-08-11 |
| SK280537B6 (sk) | 2000-03-13 |
| CA2073633A1 (en) | 1993-01-12 |
| US5409935A (en) | 1995-04-25 |
| CZ81696A3 (en) | 1997-05-14 |
| JPH05186350A (ja) | 1993-07-27 |
| DK0528164T3 (da) | 1996-09-30 |
| AU1959192A (en) | 1993-01-14 |
| CZ216092A3 (en) | 1993-01-13 |
| GR3020233T3 (en) | 1996-09-30 |
| RU2126407C1 (ru) | 1999-02-20 |
| CA2073633C (en) | 2003-09-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUP9600448A2 (hu) | Naftilvegyületek, e vegyületeket tartalmazó gyógyszerkészítmények, eljárás előállításukra, intermedierjeik és alkalmazásuk | |
| ATE122355T1 (de) | 2-substituierte adenosinderivate und pharmazeutische zusammensetzungen zur verwendung gegen infektionskrankheiten. | |
| ES2000823A6 (es) | Metodo para la produccion de compuestos analogos a la vitamina d | |
| DE69116135D1 (de) | Verwendung von alpha-tocopherolphosphat oder eines derivates davon zur herstellung kosmetischer dermatologischer oder pharmazeutischer präparate | |
| ATE138573T1 (de) | Verwendung von xanthinderivaten zur herstellung eines arzneimittels zur behandlung von sekundären nervenzellschäden und funktionsstörungen nach schädel-hirn-traumen | |
| GR3030020T3 (en) | Guanidinyl alkyl-1,1- bis phosphonic acid derivatives, process for their preparation and use. | |
| ATE92316T1 (de) | Verwendung von l-carnitinderivaten zur herstellung eines arzneimittels zur therapeutischen behandlung von peripheren neuropathien. | |
| DE3888340D1 (de) | Verwendung von 1,4-disubstituierten-Piperidinyl-Verbindungen zur Herstellung eines Arzneimittels zur Behandlung von Schlaflosigkeit. | |
| EP0398720A3 (en) | Piperazine derivatives | |
| DE3873578D1 (de) | Verwendung von tetrahydrobenz(c,d)indol-6-carboxamiden zur herstellung von arzneimitteln zur behandlung von angstzustaenden. | |
| GR3017751T3 (en) | N-phenyl-2-cyano-3-hydroxycrotonic acid amid derivatives and their use as medicaments having immunomodulating properties. | |
| ATE161725T1 (de) | Verwendung von phosphatdiestern zur behandlung von erkrankungen der retina | |
| ZA909886B (en) | Novel therapeutic application of fluoroquinolone derivatives | |
| HUT50325A (en) | Process for producing bisphenylalkyl piperazine derivatives and pharmaceutical compositions comprising same as active ingredient | |
| ES8604960A1 (es) | Procedimiento para preparar derivados de 1,6-naftiridina | |
| AU560542B2 (en) | Pyridazine derivatives which have c.n.s. activity | |
| ES8308559A1 (es) | Un procedimiento para la preparacion de nuevos derivados de quinazolina. | |
| ZA896991B (en) | New thienyloxyalkylamine derivatives,process for their preparation and medicaments containing them | |
| ES466168A1 (es) | Procedimiento para la preparacion de nuevos derivados de cromonas dotados de actividad medicamentosa | |
| ATE181503T1 (de) | Verwendung von idazoxan und derivaten zur herstellung eines arzneimittels zur behandlung von parkinsonismus und seiner evolution | |
| EP0242230A3 (en) | Pyrido û1,2-a¨ pyrimidine derivatives | |
| ATE81466T1 (de) | Verwendung von 2-oxo-imidazolidin-derivaten zur prophylaxe und zur behandlung von herzinsuffizienz. | |
| DE3776171D1 (de) | 1-styrensulfonyl-2-oxo-5-hydroxy-pyrrolidine, ihre vorprodukte und verfahren zur herstellung, sie enthaltende zusammensetzungen und ihre anwendung als heilmittel. | |
| ZA885358B (en) | Uricosuric composition | |
| MX11959A (es) | Procedimiento de preparacion de nuevos derivados de 1-aril-sulfonil-1, 5-dihidro-2h-pirrol-2-ona y producto obtenido. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition | ||
| 8327 | Change in the person/name/address of the patent owner |
Owner name: AVENTIS PHARMA DEUTSCHLAND GMBH, 65929 FRANKFURT, |
|
| 8327 | Change in the person/name/address of the patent owner |
Owner name: SANOFI-AVENTIS DEUTSCHLAND GMBH, 65929 FRANKFURT, |
|
| R071 | Expiry of right |
Ref document number: 528164 Country of ref document: EP |